ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

October 30, 2007 09:15 ET

ALDA Seeks Registration of New Antiseptic Skin Cleanser

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 30, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") has applied to Health Canada for a Drug Identification Number ("DIN") for a new antiseptic skin cleanser. The registration being sought is under a Category IV Monograph which allows Health Canada to provide an automatic registration, usually within 60 days, of infection control products that contain specified levels of anti-microbial ingredients.

As announced previously by ALDA, the services of Group 270 and Cowie and Fox have been engaged to create a new name, logo and retail marketing program for ALDA's T36® Personal Disinfectant spray. The new antiseptic skin cleanser compliments the T36® Personal Disinfectant spray and both products will be marketed under the new name.

The new antiseptic skin cleanser is more powerful and provides a higher level of infection control than standard alcohol-based hand rubs. Bundled with the T36® Personal Disinfectant spray under the new name, the two products will offer the consumer a versatile package of infection control products for use in the home or while traveling.

Dr. Terrance Owen, President & CEO, states, "The antiseptic skin cleaner ties in well with our strategy of introducing effective new products to the consumer market to alleviate concerns about the transmission of infectious diseases. We have completed a search of a new name proposed by Cowie and Fox and will now seek verification that the name can be registered."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    (604) 521-8322 (FAX)
    or
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    (604) 521-8300 Ext. 3
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com